A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee

<div><p>Objective</p><p>The Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A) is being investigated as a treatment for knee pain from osteoarthritis.</p><p>Methods</p><p>This was a multicenter randomized, vehicle-controlled, double-blind, parallel study designed to evaluate the safety and efficacy of two doses of an intra-articular injection of LMWF-5A. Patients with symptomatic knee osteoarthritis were randomized 1∶1∶1∶1 to receive a single 4 mL or 10 mL intra-articular knee injection of either LMWF-5A or vehicle control (saline). The primary efficacy endpoint was the difference between treatment groups in the Western Ontario and McMaster Universities (WOMAC) pain change from baseline over 12 weeks. Safety was examined as the incidence and severity of adverse events (AEs).</p><p>Results</p><p>A total of 329 patients were randomized and received treatment. LMWF-5A resulted in a significant decrease in pain at 12 weeks compared to vehicle control (−0.93 vs −0.72; estimated difference from control: −0.25, p = 0.004); an injection volume effect was not observed (p = 0.64). The effect of LMWF-5A on pain was even more pronounced in patients with severe knee OA (Kellgren Lawrence Grade IV): the estimated difference from control was −0.42 (p = 0.02). Adverse events were generally mild and were similar in patients who received vehicle control (47%) and LMWF-5A (41%).</p><p>Conclusions</p><p>This clinical trial demonstrated that LMWF-5A is safe and effective at providing relief for the pain of moderate to severe OA of the knee over 12 weeks when administered by intra-articular injection into the knee.</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="http://clinicaltrials.gov/show/NCT01839331" target="_blank">NCT01839331</a></p></div

Summary of the percent improvement in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscore.

<p>Summary of the percent improvement in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscore.</p

Summary of Adverse Events (AEs).

<p>Summary of Adverse Events (AEs).</p

Summary of Additional Efficacy endpoints, reported as Mean Change (SE) at Week 12, ITT.

*<p>WOMAC, Western Ontario and McMaster Universities Osteoarthritis.</p><p>Control: Saline vehicle control; Index. PGA, Patient Global Assessment of disease severity; K-L, Kellgren-Lawrence.</p>†<p>P values were calculated using mixed-effects repeated measures ANCOVA, with adjustment for baseline score.</p

Summary of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Mean Change in Pain (SE) over Time.

<p>Control: Saline vehicle control.</p>*<p>Data were collected at in-person clinic visits; data at all other Weeks were collected via telephone.</p>†<p>P values were calculated using ANCOVA, with adjustment for baseline WOMAC A pain score.</p

Demographics and baseline characteristics: ITT population.

<p>Control, saline vehicle control; BMI, Body Mass Index; K-L Grade, Kellgren Lawrence Grade; PGA, Patient Global Assessment; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.</p><p>The BMI is the weight in kilograms divided by the square of the height in meters. The PGA scores can range from 0 to 5. Scores for the WOMAC can range from 0 to 5.</p

CONSORT Flow diagram.

<p>CONSORT Flow diagram.</p